(HealthDay) — For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according …
HEALTH DAILY NEWS
Health News, Medical News, Medical conditions, Medical Tests & Procedures, Symptoms, Medical Diagnosis , Health Information, FDA alerts, Drug Watch, Product Watch, Medicine Articles, Welfare, Living